新型氮唑类化合物的合成及抗真菌活性研究

目的 设计合成含有1,3,4-二唑侧链的新型氮唑类化合物,并研究其体外抗真菌活性。方法 通过酰化、胺解、环合、亲核取代等多步反应合成了14个未见文献报道的目标化合物,其结构通过¹H NMR、MS确证,选择6种真菌为实验菌株,用微量液体稀释法检测目标化合物的体外抑菌活性。结果 所有目标化合物对实验菌株均有一定的抑制活性,尤其对白念珠菌活性较好。化合物10d、10i、10l、10n对白念珠菌的MIC₈₀值为0.003 9 μg/ml,是伊曲康唑（MIC₈₀：0.062 5 μg/ml）的16倍,是氟康唑（MIC₈₀：0.25 μg/ml）的64倍。结论 1,3,4-二唑侧链结构的引入对化合物的活性有影响,可能是侧链结构中二唑环与苯环能够与靶酶较好地结合,从而提高了化合物的活性。     

新型含喹啉和噻吩结构的抗真菌化合物的设计与合成

目的 基于喹啉类和噻吩类抗真菌化合物的构效关系,设计合成含喹啉和噻吩结构片段的新型抗真菌化合物,并测试其对白念珠菌的抑制活性。方法 以5-氰基噻吩-2-甲醛或者5-氰基噻吩-3-甲醛为起始原料,经还原氨化、氰基还原、与喹啉甲酸或异喹啉甲酸的酰胺化等反应,合成13个目标化合物,并通过¹H NMR和MS确证其化学结构,以微量液基稀释法测定这些化合物体外抗白念珠菌SC5314活性。结果 目标化合物均具有一定的抗真菌活性,其中化合物6k显示很好的抗真菌活性,MIC₈₀值为0.5 μg/ml,与对照药氟康唑相当。结论 所设计合成的含喹啉和噻吩结构片段的新型化合物具有较好的体外抗真菌活性,值得深入研究。     

没食子酰哌嗪类化合物的合成及抗真菌作用研究

目的 设计合成没食子酰哌嗪衍生物,考察其对耐药真菌的抗菌活性。方法 以三甲氧基没食子酸为原料,在PyBOP/DIEA存在下与哌嗪反应得到中间体,在脱保护后与相应的酸缩合,最后脱甲基得到目标化合物。采用美国国家临床实验室标准委员会（CLSI）推荐方法,将目标化合物对2株临床分离的耐药白色念珠菌株进行体外抗真菌活性试验,进而与氟康唑（8 μg/ml）联用,开展协同抗真菌活性试验。结果 共合成了11个化合物,其中6个化合物表现出优于没食子酸的抗真菌活性。结论 没食子酰哌嗪可以提高没食子酸的抗真菌活性,没食子酸酰结构是重要的药效团,若引入桂皮酸或2,3-二氯苯甲酸可以进一步提高活性。     

山胡椒内生真菌Trichoderma sp. SHJN1和Perenniporia sp. SHJG1的抗肿瘤活性成分研究

目的 从民族药山胡椒内生真菌Trichoderma sp.SHJN1和Perenniporia sp.SHJG1的代谢物中寻找活性先导化合物。方法 采用正相硅胶、反相硅胶、Sephadex LH-20凝胶及制备型HPLC等对Trichoderma sp.SHJN1和Perenniporia sp.SHJG1发酵物进行分离纯化，再通过NMR、ESI-MS等鉴定化合物结构，同时采用人乳腺癌细胞（MCF-7）和人肺癌细胞（A549）对这些化合物的抗肿瘤活性进行初步评价。结果 从2株内生真菌次级代谢产物中共分离鉴定了12个化合物：alantrypinone （1）、oryzalactam （2）、phomoindene A （3）、cis-gregatin B （4）、huaspenone B （5）、stigmasta-7，22-dien-3β，5α，6α-triol （6）、ergosterol （7）、1-deoxy-2-demethylviridiol （8）、viridiol （9）、trichodermamides A （10）、chromone （11）、对-羟基苯乙酸（12）。抗肿瘤活性评价结果显示，化合物3 抑制MCF-7细胞增殖活性IC₅₀为（62.9±1.02）μmol·L^-1[顺铂（cisplatin，DDP） IC₅₀为（30.1±1.67）μmol·L^-1]；化合物8 和9 抑制A549细胞增殖活性的IC₅₀分别为（34.6±1.57）μmol·L^-1和（44.9±1.74）μmol·L^-1[DDP IC₅₀为（20.6±1.42）μmol·L^-1]。结论 化合物3 ，8 和9 具有潜在抗肿瘤活性。     

去甲泽拉木醛的体外抗真菌作用研究

目的 研究去甲泽拉木醛的体外抗真菌作用。方法 采用微量液基稀释法测定去甲泽拉木醛与氟康唑单独应用于23株真菌的最低抑菌浓度（MIC）,以棋盘式微量液基稀释法测定两药联合抗耐药白念珠菌的协同指数（FICI）,判断两药联合抗菌效果;并通过纸片扩散实验直观验证两药联合的协同作用。最后通过CCK-8法测定去甲泽拉木醛的细胞毒性。结果 去甲泽拉木醛单用时呈现广谱的抗真菌作用,MIC范围为4~32 g/L。两药联用时,可将氟康唑的有效浓度从大于64 g/L降至0.25 g/L,FICI值介于0.129~0.254之间,两药表现出协同抗耐药白念珠菌作用。CCK-8结果显示,去甲泽拉木醛在高于MIC值4倍浓度下才展示出细胞毒性。结论 去甲泽拉木醛表现出较好的抗真菌作用,与氟康唑联合时有很好的协同效果,且毒性较低。     

四唑化合物开环反应、晶体结构及相关抗微生物作用研究

目的 为了解决日益严重的耐药性问题,合成得到了四唑开环化合物3。方法 5-氨基四唑1和4-乙酰氨基苯磺酰氯2在碳酸钾存在下反应得到四唑开环化合物3,并采用倍比稀释法和棋盘法测试了化合物的抗微生物活性及与临床药物的联用效果,最后使用紫外-可见光谱法测试了化合物与小牛胸腺DNA的相互作用。结果 X-射线单晶衍射证实5-氨基四唑断键开环生成叠氮化物3含有一个结晶水分子,属于P-1空间群,晶胞参数a = 7.5554(5) Å,b = 8.8163(4) Å,c = 11.0516(7) Å,a = 75.463(5) °,b = 89.813(5) °,g = 69.166(6) °。化合物通过氧原子、氮原子和氢原子形成氢键,进而形成三维超分子结构。化合物的抗细菌和抗真菌活性,结果表明所合成化合物的对所测试的细菌和真菌显示了较弱到中等(MIC = 64~256 mg·mL^-1)的抑制活性。化合物与临床药物联用后,明显增强了抗微生物能力,显示较好的协同作用效果。化合物3与小牛胸腺DNA相互作用的紫外吸收光谱显示,化合物可能通过嵌入DNA形成复合物,从而发挥抗微生物作用。结论 化合物3可作为潜在的临床抗微生物候选药物。     

海南红树林内生真菌Fusarium sp. HSL-3次级代谢产物研究

目的 研究海南红树林内生真菌Fusarium sp. HSL-3次级代谢产物,并对其进行抗炎和抗肿瘤活性筛选。方法 采用大米培养基对菌株静置培养,同时采用柱层析色谱法和HPLC对该真菌的次级代谢产物进行分离纯化,并且通过核磁共振及质谱等有机波谱手段,对得到的化合物进行结构鉴定。结果 共分离得到8个化合物,分别为lateritin(1)、4-carbomethoxy-6-hydroxy-2-quinolone(2)、3,5-dimethoxydihydrofusarubin D(3)、anhydrofusarbin(4)、3,3''-methylene-bis (4-hydroxybenzaldehyde)(5)、crypticin B(6)、vanillyl alcohol(7)和3,4-dihydroxyphenylaceticacid(8),其中化合物2和5为首次从镰刀菌属Fusarium中分离得到。化合物3和5对RAW264.7细胞表现出良好的抗炎活性(化合物3在50 µmol·L^-1时的NO抑制率为87%,化合物5在50 µmol·L^-1时的NO抑制率为71%),而化合物1对非小细胞肺癌细胞A549有显著的细胞毒活性,IC₅₀值为(7.92±0.27)µmol·L^-1。结论 从海南红树林内生真菌Fusarium sp. HSL-3中分离得到的化合物3和5具有较强的抗炎活性,化合物1有显著的抗肿瘤活性。     

高效液相色谱法测定新保肾片中芦荟大黄素、大黄酸、大黄素、大黄酚和大黄素甲醚的含量

目的 建立新保肾片中芦荟大黄素、大黄酸、大黄素、大黄酚和大黄素甲醚的含量测定方法,为生产质量提供保障。方法 采用高效液相色谱法测定,色谱柱为Lichrospher-C₁₈柱(250 mm ×4.6 mm,5 μm),流动相为甲醇:0.1%磷酸溶液(7030),流速为1.0 ml/min,柱温为35 ℃,检测波长为254 nm。结果 芦荟大黄素、大黄酸、大黄素、大黄酚和大黄素甲醚分别在2.30~18.4 μg/ml(r=1.0)、2.930~23.44 μg/ml(r=1.0)、5.00~40.0 μg/ml(r=1.0)、14.870~118.96 μg/ml (r=0.999 8)、7.410~59.28 μg/ml(r=0.999 9)范围内有良好的线性关系,平均回收率分别为100.16%、102.91%、99.76%、100.32%、100.44%,RSD分别为1.58%、1.27%、1.67%、1.33%、1.03%(n=9)。结论 该方法准确易行,便于质量控制。     

2014—2017年解放军总医院海南分院真菌分布及耐药性分析

目的 了解2014—2017年解放军总医院海南分院真菌的分布和耐药特点,为促进抗真菌药的合理应用、有效减缓真菌耐药提供参考。方法 提取解放军总医院海南分院2014年1月—2017年12月临床真菌分离和药敏相关数据,分析真菌的分布特征及其对常用抗真菌药的耐药率和变化趋势。结果 共纳入1 048份阳性真菌样本,呼吸道标本占41.89%,60岁以上患者（61.45%）和重症医学科（25.48%）分布比例最高;共分离出1 329株真菌,白色念珠菌、念珠菌属、热带念珠菌分别占24.53%、15.80%、13.69%。各种念珠菌对两性霉素B和5-氟胞嘧啶的敏感率基本保持在90%以上;热带念珠菌对伊曲康唑耐药率最高,达10%～20%,对氟康唑和伏立康唑的耐药率亦高于两性霉素B和5-氟胞嘧啶;白色念珠菌对伊曲康唑和伏立康唑的耐药率呈逐年快速上升趋势。结论 白色念珠菌和热带念珠菌感染应慎用唑类抗真菌药;两性霉素B和5-氟胞嘧啶是念珠菌感染的有效选择。     

维拉帕米对抗阿霉素的中国仓鼠卵巢上皮细胞抗药性的逆转作用

非细胞毒性剂量的维拉帕米(Ver)3μg/ml,增强阿霉素(ADM)对抗阿霉素的中国仓鼠卵巢上皮细胞(RC₁)的生长抑制达10倍。用集落形成法测定表明:Ver 3μg/ml能降低RC₁的IC₅₀值,即从1.2μg/ml降至0.08μg/ml,逆转抗药性达15倍。由于Ver增强ADM在RC₁细胞的积累,从而增强ADM对RC₁细胞的毒性,用流式细胞光度计,研究Ver逆转抗药性机制,发现Ver与ADM合用,能阻断RC₁细胞在G₂+M期。     

Synthesis and evaluation of 2,6-piperidinedione derivatives as potentially novel compounds with analgesic and other CNS activities

New 2,6-piperidinediones 2_a–g and 4_a–d were prepared by initial condensation of aromatic aldehydes or cycloalkanones with cyanoacetamide to give α-cyanocinnamides l_a–g or cycloalkylidenes 3_a,b which underwent Michae1 addition with ethyl cyanoacetate or diethylmalonate. Compounds 4_a–d were alkylated by various alkyl halides to produce the N-alkylated 2,6-piperidinedione derivatives 5_a–m. Some new selected compounds 2_a–c,f, 4_a–d & 5_e,h,j were pharmacologically evaluated for potential anticonvulsant, sedative and analgesic activities. These compounds exhibited significant anticonvulsant and analgesic effects after a single I.P. administration 100 mg/kg b.wt. . On the other hand all the investigated compounds induced hypnotic activity and prolonged the phenobarbital sodium- induced sleep as compared with the control group and the most potent compound was found to be 2_f.     

鼻渊净胶囊的HPLC指纹图谱研究

目的 建立鼻渊净胶囊的高效液相色谱(HPLC)指纹图谱.方法 采用Agilent SB-C18(4.6 mm×250 mm,5μm)色谱柱,乙腈-水为流动相、以1.0 ml/min流速行梯度洗脱,检测波长210 nm,柱温30℃,洗脱时间为80 min.采用中药色谱指纹图谱相似度评价系统(2004A版)对检测出色谱进行...     

NEURAMIDE STIMULATES ADRENOCORTICOTROPIN BUT NOT PROLACTIN RELEASE FROM RAT PITUITARY

Neuramide (NMD), a substance found in crude preparations of porcine stomach extract, is a viral inhibitor that also has putative immunostimulatory effects. The effects of NMD on stress-hormone (ACTH and prolactin—PRL) release were assessed inin vivoandin vitrostudies. In the former, blood levels of corticosterone and PRL were measured in NMD-treated male rats.In vitroexperiments were performed to evaluate the effects of NMD and three of its fractions (obtained with high performance liquid chromatography) on ACTH and PRL release from perfused rat pituitary slices. NMD increased plasma corticosterone levelsin vivoand produced dose-dependent increases inin vitropituitary release of ACTH. No effects on PRL secretion were observedin vivoorin vitro. The stimulatory effects on ACTH release were caused by the NMD fraction with a molecular weight of >5000<10000Da.     

EFFECT OF POLICOSANOL SUCCESSIVE DOSE INCREASES ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS

Policosanol is a cholesterol-lowering drug with hypocholesterolemic effects demonstrated in experimental models, healthy volunteers and type II hypercholesterolemic patients. In addition, antiplatelet effects of policosanol have been shown in experimental models and healthy volunteers. The effect of successively increasing doses of policosanol on platelet aggregation was investigated in a randomized, placebo-controlled, double-blind study conducted in 37 healthy volunteers. The volunteers were on a placebo-baseline period (two tablets per day) for 7 days and thereafter they received randomly, under double-blind conditions, placebo or policosanol (10mgday⁻¹) for 7 days. After this period dosage was doubled to 20mgday⁻¹for the next 7 days and then again doubled to 40mgday⁻¹, while the control group received placebo tablets all the time. Platelet aggregation as well as coagulation time was measured at baseline and after each dosing step. Results showed that antiplatelet effects of policosanol were successfully enhanced throughout the study, thus suggesting a dose-dependent relationship. No significant effect was reached during the first dosing period, but significant reductions of epinephrine and ADP-induced platelet aggregation were observed after the second one. Finally, a significant inhibition of platelet aggregation induced by all the agonists was observed at the last dosing step. Coagulation time remained unchanged during the trial.     

Investigation of the prevalence of tetQ, tetX and tetX1 genes in Bacteroides strains with elevated tigecycline minimum inhibitory concentrations

In this study, the antibiotic susceptibilities to tigecycline and tetracycline of 35 selected Bacteroides fragilis group strains were determined by Etest, and the presence of tetQ, tetX, tetX1 and ermF genes was investigated by polymerase chain reaction (PCR). tetQ was detected in all 12 B. fragilis group isolates (100%) exhibiting elevated tigecycline minimum inhibitory concentrations (MICs) (≥8 μg/mL) as well as the 8 strains (100%) with a tigecycline MIC of 4 μg/mL, whilst tetX and tetX1 were present in 15% and 75% of these strains, respectively. All of these strains were fully resistant to tetracycline (MIC ≥ 16 μg/mL). On the other hand, amongst the group of strains with tigecycline MICs < 4 μg/mL (15 isolates), tetQ, tetX and tetX1 were found less frequently (73.3%, 13.3% and 46.7%, respectively). All but two strains harbouring the tetQ gene in this group were non-susceptible to tetracycline, with a MIC > 4 μg/mL. These data suggest that in most cases tigecycline overcomes the tetracycline resistance mechanisms frequently observed in Bacteroides strains. However, the presence of tetX and tetX1 genes in some of the strains exhibiting elevated MICs for tigecycline draws attention to the possible development and spread of resistance to this antibiotic agent amongst Bacteroides strains. The common occurrence of ermF, tetX, tetX1 and tetQ genes together predicted the presence of the CTnDOT-like Bacteroides conjugative transposon in this collection of Bacteroides strains.     

INDIRECT PARASYMPATHOMIMETIC ACTIVITY OF THE CLASS III ANTIARRHYTHMIC SUBSTANCE / -SOTALOLIN VITRO: REVERSIBLE INHIBITION OF CHOLINESTERASE ISOENZYMES FROM BLOOD AND THE HUMAN CENTRAL NERVOUS SYSTEM

Inhibitory effects of the class III antiarrhythmic compound / -sotalol on acetylcholinesterase (AChE; EC 3.1.1.7) isoenzymes of both erythrocytes and the human caudate nucleus and on serum cholinesterase (ChE; EC 3.1.1.8) were studiedin vitrousing a spectrophotometric kinetic assay with acetylthiocholine (ASCh) as substrate. Sotalol concentrations in the assays varied from 0.32 to 3.2m . All isoenzymes studied were inhibited by / -sotalol in a reversible and concentration-dependent manner. Double reciprocal plots of the reaction velocity against varying ASCh concentrations revealed that / -sotalol reduced substrate affinity (apparent Michaelis constant, KM, increased) of serum ChE, but did not change the enzyme's maximal rate of ASCh hydrolysis (V_max). Thus, / -sotalol inhibition of serum ChE was of the competitive type (rate constant for reversible competitive inhibition: K_i=0.51m ). In contrast, / sotalol reduced the maximal reaction velocity of the AChE isoenzyme from the central nervous system (caudate nucleus), but had no influence on substrate affinity of the enzyme (K_Mwith ASCh unchanged) indicating purely non-competitive inhibition kinetics (rate constant of reversible non-competitive inhibition: K_i′=0.44m ). / -sotalol inhibition of erythrocyte AChE was of mixed competitive/non-competitive type (K_i=0.31m , K_i′=0.49m ). Non-competitive / -sotalol inhibition of caudate nucleus AChE and the non-competitive component of erythrocyte AChE inhibition cannot be overcome by increased concentrations of the cholinergic transmitter acetylcholine (ACh). Peak / -sotalol plasma levels as described in the literature for both humans (15μ ) and experimental animals (dogs: 18μ ; rats: 260μ ) as well as maximal myocardial concentrations of the substance (dogs: 46μ ; rats: 478μ ) are in the range of about 2% to 100% of the sotalol inhibition rate constants determined in the present paper for cholinesterase isoenzymesin vitro. Thus, / -sotalol inhibition of ACh hydrolysisin vivomay contribute to both the well known antiarrhythmic potential and proarrhythmic side effects of the compound.     

AMELIORIATION OF CHEMICALLY-INDUCED HEPATOCYTE INJURY BY CYCLOSPORINE A

Cyclosporine A, beside its current applications, possesses potential hepatoprotective effects. This study was directed to investigate the effect of Cyclosporine A pretreatment on hepatic injury due to carbon tetrachloride (CCl₄) and -galactosamine. Rats were injected by two successive doses of Cyclosporine A (5mgkg⁻¹day⁻¹). Six hours after the second dose, 1mlkg⁻¹of CCl₄was administered i.p. Effects associated with Cyclosporine A pretreatment were examined by using isolated hepatocytes and hepatocytes that were immobilized and continuously perfused. -Galactosamine (5m ) was added directly to the perfusion medium. After isolation, hepatocytes were examined histologically by light and electron microscopy, immobilized and perfused for further metabolic functional activity evaluation. Cyclosporine A pretreatmentin vivoproduced hepatoameliorative effects of various degrees which were statistically significant as manifested by: (1) an increased trypan blue exclusion after CCl₄; (2) an improved ureagenesis after CCl₄; (3) a reduction in the lipid droplets accumulation in the cytoplasm produced by CCl₄administration; (4) well preserved cytoplasmic organelles as mitochondria, endoplasmic reticulum ER, nuclear chromatin structures that were altered by CCl₄; and (5) an increased hepatocytes survival in the agarose gel matrix, reduction of LD leakage and improvement of ureagenesis after -galactosamine addition to the perfusion medium. The beneficial effect of Cyclosporine A pretreatment in modifying hepatotoxicity of chemical insults merits further studies.     

喙果黑面神化学成分研究

目的研究大戟科植物喙果黑面神(Breynia rostrata Merr.)的化学成分。方法利用硅胶、凝胶等色谱技术分离纯化化学成分,根据化合物的理化性质和光谱数据进行结构鉴定。结果从喙果黑面神的正丁醇萃取部分分离得到4个化合物,分别鉴定为6-O-甲基丙酰基-α-D-吡喃葡糖(6-O-methylpropanoyl-α-D-glucopyranose,1);4″-苯酚基-6-O-甲基丙酰基-β-D-吡喃葡糖苷(4″-phenolic-6-O-methylpropanoyl-β-D-glucopyranoside,2);1-O-没食子酰基-β-D-吡喃葡糖苷(1-O-galloyl-β-D-glucopyranoside,3);熊果苷(arbutin,4)。结论化合物1和2为新化合物,3和4均为首次从该种植物分离得到。     

EFFECTS OF 2-GUANIDINE-4-METHYLQUINAZOLINE ON GASTRIC ACID SECRETION IN RATS

In this study 2-guanidine-4-methylquinazoline (2-GMQ) appeared to decrease basal and stimulated gastric acid secretion, while structurally related compounds as dimethyl- biguanide, cyanoguanidine and 2-cyanoamino-4-methylpyrymidine did not. Thus, there is an antisecretory effect when the biguanide group is associated with a lipophilic structure. The antisecretive effects exerted by 2-GMQ are associated with anti H₂-histamine activity.The anti H₂-histamine nature of the effects of 2-GMQ was confirmed by the capacity of this compound of depressing the chronotropic activity of the isolated guinea pig auricle increased by histamine, as well as relaxant activity in rat uterus contracted by histamine, since both preparations are rich in H₂-histamine receptors.     

栝楼不同药用部位质量控制的研究进展

瓜蒌子、瓜蒌皮、瓜蒌、天花粉来源于栝楼的不同药用部位,4味药材均为常用的大宗药材,现行版《中国药典》对其制定的质量标准过于简单,无法科学合理地控制其质量。本文对瓜蒌子、瓜蒌皮、瓜蒌、天花粉安全性和有效组分的研究进行综述,明确了相关研究存在的问题并针对问题提出建议,为科学全面的药材及饮片标准的制定提供参考依据。